MSC and Costimulation Inhibitor Compositions for Graft Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for steroid-resistant severe graft-versus-host disease and other autoimmune and inflammatory conditions face challenges due to the limitations of mesenchymal stem cells (MSCs) and costimulation blockade therapies, including transient effects and adverse events, as well as resistance from memory T cells and complexities in translating mouse models to humans.
Innovation Solution
Combining mesenchymal stem cells (MSCs) with exogenous costimulation inhibitors that have an extended in vivo half-life, creating a synergistic effect to enhance treatment efficacy and safety by modulating the immune system, thereby improving transplantation outcomes and addressing autoimmune and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells (MSCs) are used to treat steroid-resistant severe graft-versus-host disease, then immune modulation and anti-inflammatory effects are achieved, but the treatment effects are transient and require repeated administrations
Solution Approach 1:
The patent combines MSCs with costimulation inhibitors (such as CTLA4Ig, anti-CD40L antibodies) to create a synergistic treatment approach. The costimulation inhibitors block co-stimulatory signals (B7-CD28, CD40-CD40L pathways) to induce T cell anergy, while MSCs provide immunomodulation and anti-inflammatory effects, together achieving more durable treatment outcomes than either therapy alone
Solution Approach 2:
The costimulation inhibitors are administered to establish prolonged immune suppression and T cell anergy before or concurrent with MSC transplantation. This preliminary action creates a favorable immunosuppressive environment that enhances MSC engraftment and prolongs their therapeutic effects, addressing the transient nature of MSC-only treatment
2Reliability
If costimulation blockade is used to replace immunity with tolerance, then T cell anergy and graft survival are improved, but memory T cells with reduced reliance on costimulation pathways remain resistant and transplant rejection occurs
Solution Approach 1:
The patent combines costimulation inhibitors with MSCs to address memory T cell resistance. While costimulation inhibitors block co-stimulatory pathways to induce anergy in naive T cells, MSCs contribute alternative immunomodulatory mechanisms including induction of regulatory T cells, direct inhibition of memory T cell proliferation, and anti-inflammatory cytokine production, thereby overcoming the limitations of costimulation blockade alone
Solution Approach 2:
MSCs act as intermediary cells that bridge the gap left by costimulation inhibitors. They provide direct contact-dependent immunomodulation to memory T cells and produce soluble factors (TGF-β, IL-10, PGE2) that suppress memory T cell responses through pathways independent of costimulation blockade, thereby extending the tolerance-inducing effect to memory T cell populations
3Reliability
If MSCs are genetically modified to express costimulation inhibitors, then local immunosuppression is achieved, but the therapeutic effect is reduced compared to unmodified MSCs
Solution Approach 1:
The patent uses unmodified MSCs in combination with systemically administered costimulation inhibitors rather than genetically modified MSCs. This approach preserves the full immunomodulatory potential of native MSCs while adding the benefit of prolonged costimulation blockade, achieving synergistic effects that are superior to genetically modified approaches
Solution Approach 2:
Unmodified MSCs maintain their natural immunomodulatory functions and can be administered without complex genetic manipulation. The costimulation inhibitors are administered separately to provide additional immunosuppression, allowing both therapies to work through their native mechanisms without interference from genetic modification, thereby preserving therapeutic efficacy
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising mesenchymal cells (MSCs) and additional agents for blocking co-stimulation of the immune system. The compositions may optionally further comprise a therapeutic cell, a therapeutic tissue, and/or a therapeutic organ implant. Additionally, the instant invention pertains to medical uses of such compositions in immune-mediated diseases and disorders, in essentially all inflammatory and/or autoimmune diseases and conditions, and also in transplantation-related conditions.